Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 5/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23033458 | 0.85 | BCHE (0.68) | GAABCHETAAR1MEN1KMT2A | |
| SCHEMBL10447514 | 0.81 | L3MBTL1 (0.59) | GAABCHETAAR1MEN1KMT2A | |
| SCHEMBL21153878 | 0.79 | GAA (0.64) | GAABCHETAAR1MEN1KMT2A | |
| SCHEMBL28724147 | 0.79 | LMNA (0.60) | GAABCHECA12CA1CA2 | |
| Phenylethyl Alcohol SCHEMBL28230089 | 0.78 | TDP1 (0.55) | GAATAAR1MEN1KMT2ADRD2 | |
| SCHEMBL50487 | 0.78 | AOC3 (0.54) | TAAR1DRD2DRD4DRD3 | |
| SCHEMBL5216666 | 0.76 | GAA (0.73) | GAABCHETAAR1MEN1KMT2A | |
| SCHEMBL15401251 | 0.76 | AOC3 (0.52) | TAAR1DRD2DRD4DRD3 | |
| SCHEMBL6658911 | 0.76 | AOC3 (0.52) | TAAR1DRD2DRD4DRD3 | |
| SCHEMBL28366510 | 0.76 | AOC3 (0.52) | TAAR1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | ACELOT, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | GAA 401/4885BCHE 36/4885TAAR1 2452/4885 |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | APP, PSEN2, PSEN1 | GAA 401/4885BCHE 36/4885TAAR1 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.